WhereScape Announces Cloud Data Warehouse Automation for Snowflake
WhereScape, the leading provider of data infrastructure automation software, today announced WhereScape® automation for Snowflake, an offering designed to help IT organizations speed up the delivery of cloud-based data infrastructure projects. WhereScape will showcase the new offering this week during the TDWI Conference in Anaheim, Calif.
WhereScape automation for Snowflake automates key development and operations workflows for Snowflake customers based on the native functions, wizards and best practices of Snowflake and incorporates data warehouse modelling methodologies such as 3NF, dimensional and Data Vault 2.0. Snowflake provides cloud-based data warehousing solutions that deliver the performance, elasticity, scalability, concurrency and simplicity needed to store and analyze all of an organization’s data in one location.
“The combination of WhereScape’s data warehouse automation tools with Snowflake's zero administration service is perfect for enabling our customers to be successful with agile data warehousing,” said Kent Granziano, senior technical evangelist of Snowflake. “WhereScape automation for Snowflake makes it possible for organizations to start using Snowflake faster and more easily by simplifying and automating the design, build and population of data warehouse tables. Our customers will benefit from the effortless, simple, drag and drop interface, with which they can point at a source database, or even flat files, then load that data right into Snowflake with zero coding! That is agile.”
“Our health and life sciences clients rely on us to execute flawless marketing campaigns and deliver customer insights from across our many digital platforms,” said Peter Nilsson, Chief Technology Officer of Aptus Health. “To that end, we’re leveraging WhereScape’s ability to ease our design and implementation effort as we develop our fully-integrated warehouse on Snowflake. WhereScape's tools will save us thousands of engineering hours, promote implementation accuracy, and accelerate our time to delivery. And since WhereScape natively supports Snowflake, we can use the generated code without having to tailor it to our target environment—letting us focus on generating the insights that will drive our business forward.”
WhereScape automation for Snowflake includes:
- WhereScape® 3D for Snowflake helping IT teams quickly and effectively tackle the upfront planning, modelling and design needed to rapidly put Snowflake to use. WhereScape 3D data discovery and profiling tools allow customers to more easily understand new data sources and leverage automation built for Snowflake to quickly build, test and iterate on prototypes with business users.
- WhereScape® RED for Snowflake, an integrated development environment, providing IT teams the ability to develop, deploy and operate Snowflake data infrastructure faster. With built-in automation based on native Snowflake functions, wizards and best practices, customers can eliminate the time-intensive hand-coding involved in data infrastructure development. Advanced DevOps capabilities allow users to quickly establish new environments, continuously migrate changes and operate data processing in Snowflake – all with best practices automatically utilized. WhereScape RED for Snowflake automatically generates and maintains user and technical documentation such as data lineage, track back, and track forward for future reference, lifting a time-intensive burden off IT teams.
- WhereScape® Data Vault Express™ for Snowflake, an integrated combination of WhereScape 3D and WhereScape RED embedded with Data Vault 2.0 specific capabilities, empowering teams to more practically deliver data vaults.
"Whether large or small, organizations today are grappling with the strategy, tactics and timing of moving on-premises data into the cloud," said Matt Aslett, Research Director of 451 Research. "Automating data movement and populating data warehouse tables in the cloud promises to smooth the transition path for IT teams, providing more time to focus on the business value of the transition and associated analytics applications.”
“IT faces enormous pressure to deliver decision-support information faster than ever before,” said Mark Budzinski, CEO of WhereScape. “As the growth of data doubles nearly every other year, organizations are increasingly feeling squeezed for resources and time. Many look to the cloud to address these challenges. We are excited to help Snowflake customers maximize their adoption of a cloud strategy and fast-track their use of Snowflake by addressing head-on the thrash and hidden costs of designing, developing, deploying and operating data infrastructure.”
Mark Budzinski, CEO of WhereScape, and Jon Bock, VP of product and partner marketing for Snowflake Computing, will discuss the offering together today on the #InsideAnalysis radio podcast at 3PM ET, with a follow-up Deep Dive Webcast at 4PM ET. Additionally, WhereScape’s Jason Laws, vice president of product management, will present today at the TDWI Leadership Summit at 2:15PM PT.
Learn more about WhereScape automation for Snowflake here
WhereScape
#InsideAnalysis podcast and Deep Dive webcast here
About WhereScape
WhereScape helps IT organizations of all sizes leverage automation to design, develop, deploy, and operate data infrastructure faster. More than 700 customers worldwide rely on WhereScape automation to eliminate hand-coding and other repetitive, time-intensive aspects of data infrastructure projects to deliver data warehouses, vaults, lakes and marts in days or weeks rather than in months or years. WhereScape has offices in Portland, Oregon; Reading, UK; Auckland, New Zealand; and Singapore. For more information, please visit www.wherescape.com
All products or company names herein may be trademarks of their respective owners.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170807005178/en/
Contact information
WhereScape
Ruth Armitage/Sarah Shkargi
wherescape@touchdownpr.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Compass Pathways Announces FDA Acceptance of IND Application for PTSD and Hosts Webinar on PTSD and TRD7.1.2026 13:30:00 EET | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, today announced that the U.S. Food and Drug Administration (FDA) has accepted its Investigational New Drug (IND) application for COMP360, enabling the initiation of a late-stage clinical trial in patients with PTSD. Compass management, along with KOL and industry leaders, will host a webinar today to discuss the company’s clinical trial plans for PTSD, as well as commercial preparations for treatment-resistant depression (TRD) from 10:00-11:30 am ET on January 7th. “PTSD is one of the most challenging mental health conditions, with approximately 13 million adults in the U.S. living with persistent symptoms and limited treatment options,” said Dr. Guy Goodwin, Chief Medical Officer at Compass Pathways. “We are pleased to advance our clinical development - the unmet need is profound, and it demands bold innovation. We believe COMP360 has the potential to tra
Stallergenes Greer Expands Venom Immunotherapy Production Capacity With Acquisition of Entomon s.r.l.7.1.2026 12:07:00 EET | Press release
Stallergenes Greer, a global leader in allergy therapeutics, today announced that it has entered into an agreement to acquire Entomon s.r.l., an Italian company specialising in the production of certified stinging-insect venom extracts, notably of the Hymenoptera order, used for the manufacture of diagnostic preparations and Venom Immunotherapy (VIT). The transaction is expected to close by the end of January. Entomon, currently recognised as the only company in Europe capable of extracting pure venom from Hymenoptera insects, produces pharmaceutical-grade insect venom using proprietary techniques (Entomon Capillary Extracted Venom®) for medical use. Through this acquisition, Stallergenes Greer bolsters its venom manufacturing capabilities and supply of raw materials for life-saving VIT treatments, whilst safeguarding patient care continuity. Hymenoptera venom allergy is the most common trigger of severe anaphylaxis in adults1. According to the EAACI guidelines on venom immunotherapy,
ARIS Announces New CEO to Lead Agentic AI-led Strategy7.1.2026 11:00:00 EET | Press release
CEO Appointment ARIS, a global leader in process intelligence and transformation software, today announced the appointment of Guillaume Bacuvier as Chief Executive Officer. Guillaume will lead ARIS through its next phase of growth as a fully standalone company, accelerating its evolution from a market leader in Process Intelligence into a foundational platform for enterprises deploying and governing Agentic AI. Guillaume brings deep international leadership experience across technology, data, and software-enabled businesses, with a proven track record of scaling global platforms and leading complex organisations. After starting as a strategic consultant at Booz Allen Hamilton, Guillaume spent over a decade at Google, rising to Vice President in EMEA where he built and scaled some of Google’s largest data-driven businesses in Europe and held P&L responsibility across multiple countries. In the last decade, Guillaume has served as CEO of multi-continent, data-centric companies including
I Squared Capital Acquires Ramudden Global, a Leader in Traffic Management and Infrastructure Safety7.1.2026 10:00:00 EET | Press release
I Squared Capital, a leading global infrastructure investment manager, today announced that, through its flagship fund, it has agreed to acquire Ramudden Global, from funds advised by Triton Partners (“Triton”), a leading European mid-market sector-specialist investor. Ramudden Global is a leading international provider of traffic management and infrastructure safety services supporting the maintenance and upgrade of essential transport and utility networks. The company operates more than 190 depots across 13 countries in Europe and North America delivering mission-critical services that help to ensure safety, regulatory compliance and continuity of service across road, utility and broader infrastructure works. This investment underscores I Squared Capital’s commitment to investing in essential, regulated, infrastructure businesses that underpin public safety, mobility and economic activity. Ramudden operates in markets where demand is steady and growing and benefits from deep commerci
RoslinCT and BOOST Pharma Announce Strategic Manufacturing Agreement to Advance Cell Therapy for Infants with Osteogenesis Imperfecta7.1.2026 10:00:00 EET | Press release
RoslinCT, a global contract development and manufacturing organization (CDMO) specializing in advanced cell therapies, and BOOST Pharma, a clinical-stage biotechnology company developing first-in-class cell therapies for rare paediatric skeletal diseases, today announced a strategic manufacturing partnership to support the development of BOOST Pharma’s cell therapy, BT-101, for the treatment of infants with Osteogenesis Imperfecta (OI), also known as brittle bone disease. Under the service agreement, BOOST Pharma has transferred its manufacturing process to RoslinCT’s state-of-the-art facilities in Edinburgh, Scotland. The partnership will progress toward GMP manufacturing of starting materials and clinical drug product, supporting Phase III clinical development of BT-101. The therapy is an allogeneic mesenchymal stem cell (MSC) product designed to address the underlying cause of OI at the earliest stages of life. BOOST Pharma was founded on pioneering science originating from Karolins
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom